3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
4
Wound Infection
2
Infections
2
Surgical Wound Infection
1
Prostatic Neoplasms
1
Laryngeal Neoplasms
1
Clinical Stage I Cutaneous Melanoma AJCC v8
1
Carcinoma, Hepatocellular
1
Bone Neoplasms
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Proton Therapy
2
Methotrexate
2
Injections
2
Ifosfamide
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Neoplasms
×
Cefazolin
×
Clear all
NCT01479283
2021-03-11
PARITY
McMaster University
Phase 3
Completed
602 enrolled